- Home
- BREA vs SYBX Comparison
BREA vs SYBX Comparison
Compare BREA & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- SYBX
- Stock Information
- Founded
- BREA 2022
- SYBX N/A
- Country
- BREA Ireland
- SYBX United States
- Employees
- BREA N/A
- SYBX N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- SYBX Health Care
- Exchange
- BREA Nasdaq
- SYBX Nasdaq
- Market Cap
- BREA 13.6M
- SYBX 13.6M
- IPO Year
- BREA 2023
- SYBX N/A
- Fundamental
- Price
- BREA $6.88
- SYBX $1.26
- Analyst Decision
- BREA
- SYBX
- Analyst Count
- BREA 0
- SYBX 0
- Target Price
- BREA N/A
- SYBX N/A
- AVG Volume (30 Days)
- BREA 18.5K
- SYBX 7.8K
- Earning Date
- BREA 01-03-2025
- SYBX 08-07-2025
- Dividend Yield
- BREA N/A
- SYBX N/A
- EPS Growth
- BREA N/A
- SYBX N/A
- EPS
- BREA N/A
- SYBX 0.21
- Revenue
- BREA $2,988,009.00
- SYBX N/A
- Revenue This Year
- BREA N/A
- SYBX N/A
- Revenue Next Year
- BREA N/A
- SYBX N/A
- P/E Ratio
- BREA N/A
- SYBX $5.82
- Revenue Growth
- BREA 151.51
- SYBX N/A
- 52 Week Low
- BREA $5.00
- SYBX $0.90
- 52 Week High
- BREA $19.50
- SYBX $1.88
- Technical
- Relative Strength Index (RSI)
- BREA 96.66
- SYBX 52.81
- Support Level
- BREA $0.66
- SYBX $1.17
- Resistance Level
- BREA $0.79
- SYBX $1.27
- Average True Range (ATR)
- BREA 0.20
- SYBX 0.04
- MACD
- BREA 0.39
- SYBX -0.01
- Stochastic Oscillator
- BREA 84.50
- SYBX 40.00
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.